Not sure how much this has been discussed on the message board, but the company very clearly stated they are in talks with the FDA on pursuing ODD for the indication of PHN with Z-160. Getting this would be huge (if, of course, the P2 results are good).
hwsi: You bet its big ODD triggers the following:
Causes the FDA to review the studies ahead of earlier applicants.
Extends both European and domestic patent life.
Waves the $736,000 filing fee.
Puts them in line for Federal incentive grants.
The PR it generates is of untold value, gets you on the front page.
Lastly it should allow for a higher asking price for the product.
Jim Long and calm